Upstream files provisional patent for thyroid cancer biomarkers

By Elaine Rigoli

Tampa, Fla., Sept. 26 - Upstream Biosciences, Inc. said it filed a provisional patent application with the U.S. Patent and Trademark Office for certain thyroid cancer biomarkers that could be useful for determining whether patients have a genetic risk of developing thyroid cancer.

The Vancouver, B.C., genetic diagnostics company said its diagnostic markers could increase the likelihood of early detection by identifying which patients have a genetic risk of developing thyroid cancer.

"The early detection of thyroid cancer is another area that our technology can be applied to. We believe that identifying individuals with disease susceptibility is a way of prevention and the future of medicine," chief executive officer Joel Bellenson said in a news release.

Upstream is developing diagnostic tests that may aid in the early detection of cancer by identifying individuals with disease susceptibility. Upstream is also developing diagnostic tests that may determine whether a drug will be useful or harmful to an individual patient based on his or her genetic profile.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.